(OTCQB:TNIB) a biotechnology company pioneering the development of?innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC") that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC.
"SEC clearance of TNIB's Form 10 registration statement is a significant milestone that will provide transparency with the investment community," said Noreen Griffin, President of TNIB. "This is a critical step toward achieving our goal of trading on a senior US stock exchange such as NASDAQ or the NYSE."